However, a Phase I/II trial of ABBV-428, a bispecific mAb targeting CD40 (as an agonist) and tumour cell marker mesothelin, was not able to replicate these promising anti-tumoural effects in ovarian cancer patients [25]. Here, CD40 is linked to ovarian cancer.